目的 探讨清肺消炎丸联合布地奈德福莫特罗吸入粉雾剂治疗慢性阻塞性肺疾病的临床疗效。方法 选取2020年2月—2021年6月新乡市第一人民医院收治的126例慢性阻塞性肺疾病患者，按照随机数字表法分为对照组和治疗组，各包括63例。对照组吸入布地奈德福莫特罗吸入粉雾剂（Ⅱ），1吸/次，2次/d。治疗组患者在对照组基础上口服清肺消炎丸，5 g/次，3次/d。两组患者连续治疗8周。观察两组的临床疗效，比较两组肺通气功能、自我评估测试量表（CAT）评分和血清炎症因子水平。结果 治疗后，治疗组总有效率（93.65%）高于对照组（80.95%）（P<0.05）。治疗后，两组的最大呼气中期流量（MMEF）、第1秒钟用力呼气容积占用力肺活量的百分比（FEV1/FVC）、第1秒用力呼气容积占预计值的百分比（FEV1% pred）显著升高（P<0.05）；治疗后，治疗组的MMEF、FEV1/FVC、FEV1% pred高于对照组，差异有统计学意义（P<0.05）。治疗后，两组的CAT评分明显降低（P<0.05）；治疗组的CAT评分低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的基质金属蛋白酶-9（MMP-9）、转化生长因子-β₁（TGF-β₁）、C反应蛋白（CRP）水平显著降低（P<0.05）；治疗后，治疗组的MMP-9、TGF-β₁、CRP水平低于对照组，差异有统计学意义（P<0.05）。结论 清肺消炎丸联合布地奈德福莫特罗吸入粉雾剂可提高慢性阻塞性肺疾病的临床疗效，改善肺通气功能，降低血清炎症因子，治疗安全性良好。

Objective To investigate the clinical efficacy of Qingfei Xiaoyan Pills combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of chronic obstructive pulmonary disease. Methods Patients (126 cases) with chronic obstructive pulmonary disease in Xinxiang First People’s Hospital from February 2020 to June 2021 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation (Ⅱ), 1 suction/time, twice daily. Patients in the treatment group were po administered with Qingfei Xiaoyan Pills on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and pulmonary ventilation function, CAT score, and serum inflammatory factors levels in two groups were compared. Results After treatment, the total effective rate of the treatment group (93.65%) was higher than that of the control group (80.95%) (P<0.05). After treatment, the MMEF, FEV1/FVC, and FEV1%pred were significantly increased in two groups (P<0.05). After treatment, the MMEF, FEV1/FVC, and FEV1% pred in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the CAT scores of two groups were significantly decreased (P<0.05). After treatment, the CAT score of the treatment group was lower than that of the control group (P<0.05). After treatment, the level of MMP-9, TGF-β₁, and CRP in two groups were significantly decreased (P<0.05). After treatment, the levels of MMP-9, TGF-β₁, and CRP in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qingfei Xiaoyan Pills combined with Budesonide and Formoterol Fumarate Powder for inhalation can improve the curative effect of chronic obstructive pulmonary disease, improve pulmonary function, and reduce airway inflammatory reaction, with good safety.

R974

河南省医学科技攻关计划联合共建项目（2018020853）